Syndax Pharmaceuticals (SNDX) Cash from Operations (2015 - 2026)

Syndax Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 50345000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 47.1% year-over-year to 50345000.0; the TTM figure through Mar 2026 stood at 278163000.0 (up 2.92% YoY), while the FY2025 annual figure was 322980000.0, down 17.49% from the prior year.
• Cash from Operations was 50345000.0 for Q1 2026 at Syndax Pharmaceuticals, up from 69488000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 22894000.0 in Q4 2022 to a low of 95162000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 55441411.76 across 5 years, with a median of 50345000.0 in 2026.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations tumbled 122.73% in 2022, then soared 47.1% in 2026.
• A 5-year view of Cash from Operations shows it stood at 22894000.0 in 2022, then plunged by 80.61% to 41349000.0 in 2023, then slumped by 38.79% to 57388000.0 in 2024, then decreased by 21.08% to 69488000.0 in 2025, then advanced by 27.55% to 50345000.0 in 2026.
• The last three Cash from Operations figures came in at 50345000.0 (Q1 2026), 69488000.0 (Q4 2025), and 70535000.0 (Q3 2025), per Business Quant data.